AU2014241442B2 - Human antibodies to GREM 1 - Google Patents

Human antibodies to GREM 1 Download PDF

Info

Publication number
AU2014241442B2
AU2014241442B2 AU2014241442A AU2014241442A AU2014241442B2 AU 2014241442 B2 AU2014241442 B2 AU 2014241442B2 AU 2014241442 A AU2014241442 A AU 2014241442A AU 2014241442 A AU2014241442 A AU 2014241442A AU 2014241442 B2 AU2014241442 B2 AU 2014241442B2
Authority
AU
Australia
Prior art keywords
ser
gly
ala
thr
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014241442A
Other languages
English (en)
Other versions
AU2014241442A1 (en
Inventor
Aris Economides
Vincent J. Idone
Lori C. Morton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2014241442A1 publication Critical patent/AU2014241442A1/en
Application granted granted Critical
Publication of AU2014241442B2 publication Critical patent/AU2014241442B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2014241442A 2013-03-14 2014-03-07 Human antibodies to GREM 1 Active AU2014241442B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361782874P 2013-03-14 2013-03-14
US61/782,874 2013-03-14
US201361883218P 2013-09-27 2013-09-27
US61/883,218 2013-09-27
PCT/US2014/021471 WO2014159010A1 (en) 2013-03-14 2014-03-07 Human antibodies to grem 1

Publications (2)

Publication Number Publication Date
AU2014241442A1 AU2014241442A1 (en) 2015-10-15
AU2014241442B2 true AU2014241442B2 (en) 2018-11-15

Family

ID=50390267

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014241442A Active AU2014241442B2 (en) 2013-03-14 2014-03-07 Human antibodies to GREM 1

Country Status (18)

Country Link
US (3) US10377817B2 (OSRAM)
EP (1) EP2970448B1 (OSRAM)
JP (2) JP6581075B2 (OSRAM)
KR (1) KR20150129718A (OSRAM)
CN (1) CN105189548A (OSRAM)
AU (1) AU2014241442B2 (OSRAM)
BR (1) BR112015021979A2 (OSRAM)
CA (1) CA2904644C (OSRAM)
CL (1) CL2015002603A1 (OSRAM)
EA (1) EA201591762A1 (OSRAM)
ES (1) ES2898620T3 (OSRAM)
HK (1) HK1220469A1 (OSRAM)
IL (1) IL240769A0 (OSRAM)
MX (1) MX369574B (OSRAM)
PH (1) PH12015501865A1 (OSRAM)
SG (2) SG10201707518YA (OSRAM)
WO (1) WO2014159010A1 (OSRAM)
ZA (1) ZA201506113B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2826790B1 (en) * 2012-03-15 2019-02-13 SNU R&DB Foundation Anti-gremlin-1 antibody
EP2970448B1 (en) 2013-03-14 2021-11-03 Regeneron Pharmaceuticals, Inc. Human antibodies to grem 1
CN109071665B (zh) 2016-04-18 2022-11-01 塞德斯医疗公司 结合人cd40的激动性抗体及其用途
CN106399316B (zh) * 2016-08-26 2019-03-01 西安交通大学第一附属医院 用于识别Gremlin-1的核酸适配子及其应用
MA46046A (fr) 2016-08-29 2019-07-03 Regeneron Pharma Anticorps anti-gremlin-1 (grem1) et procédés d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire
CN118562004A (zh) 2016-12-16 2024-08-30 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
WO2018175740A1 (en) * 2017-03-22 2018-09-27 Bluefin Biomedicine, Inc. Anti-tmeff1 antibodies and antibody drug conjugates
US12161694B2 (en) * 2017-03-24 2024-12-10 The Broad Institute, Inc. Methods and compositions for regulating innate lymphoid cell inflammatory responses
GB201802486D0 (en) * 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
EP3806898B1 (en) * 2018-06-18 2025-10-08 UCB Biopharma SRL Gremlin-1 antagonist for use in the treatment of cancer
WO2020106461A2 (en) * 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
JP7638989B2 (ja) 2019-11-21 2025-03-04 ユニティ バイオテクノロジー インコーポレイテッド Ｔｉｅ－２に対する抗体および使用方法
CA3192306A1 (en) * 2020-10-20 2022-04-28 Burkhard Ludewig Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
TW202237642A (zh) * 2021-01-08 2022-10-01 美商１０Ｘ基因組學有限公司 對冠狀病毒具有特異性的抗原結合多肽及其用途
CN116848135A (zh) * 2021-01-18 2023-10-03 苏州创胜医药集团有限公司 新颖的抗gremlin1抗体
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
CA3243581A1 (en) * 2022-04-20 2023-10-26 Kantonsspital St. Gallen ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THAT BIND PANSPECIFICALLY TO GREMLIN-1 AND GREMLIN-2 AND RELATED USES
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑
CN115786495A (zh) * 2022-10-24 2023-03-14 杭州市第七人民医院 检测基因表达量的试剂在制备尼古丁加重的糖尿病肾病的筛查试剂盒中的用途
KR20250169623A (ko) * 2023-04-13 2025-12-03 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 암 치료를 위한 grem1 길항제를 수반하는 조합 요법
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090041757A1 (en) * 2007-03-16 2009-02-12 Hanson Zhen Bone morphogenetic protein antagonist and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
WO1998033918A1 (en) 1997-02-05 1998-08-06 The Regents Of The University Of California Morphogenic proteins
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MXPA04003697A (es) 2001-10-31 2005-04-08 Alcon Inc Proteinas morfogenicas de hueso (bmp), receptores de bmp y proteinas de enlace de bmp y su uso en el diagnostico y tratamiento de glaucoma.
EP1777519A1 (en) 2001-10-31 2007-04-25 Alcon, Inc. Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
JP2008531525A (ja) 2005-02-24 2008-08-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチド製剤を安定化する化合物
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20090203041A1 (en) 2006-04-21 2009-08-13 Wei Shi Bmp4 inhibitors
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
ES2647538T3 (es) 2007-09-28 2017-12-22 Pfizer Inc. Direccionamiento a células de cáncer usando nanopartículas
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
EP2826790B1 (en) 2012-03-15 2019-02-13 SNU R&DB Foundation Anti-gremlin-1 antibody
EP2970448B1 (en) 2013-03-14 2021-11-03 Regeneron Pharmaceuticals, Inc. Human antibodies to grem 1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090041757A1 (en) * 2007-03-16 2009-02-12 Hanson Zhen Bone morphogenetic protein antagonist and uses thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHANG-LI WANG, "The bone morphogenetic protein antagonist Gremlin is overexpressed in human malignant mesothelioma", ONCOLOGY REPORTS, (2011-09-20), doi:10.3892/or.2011.1463, ISSN 1021-335X, pages 58 - 64 *
KATRI KOLI ET AL, "Bone Morphogenetic Protein-4 Inhibitor Gremlin Is Overexpressed in Idiopathic Pulmonary Fibrosis", THE AMERICAN JOURNAL OF PATHOLOGY, (2006-07-01), vol. 169, no. 1, pages 61 - 71 *
LONBERG ET AL, "Fully human antibodies from transgenic mouse and phage display platforms", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 20, no. 4, (2008-08-01), pages 450 - 459, (2008-07-21) *
MINSOO KIM ET AL, "Gremlin-1 Induces BMP-Independent Tumor Cell Proliferation, Migration, and Invasion", PLOS ONE, (2012-04-13), vol. 7, no. 4, doi:10.1371/journal.pone.0035100, page e35100 *
P. CHIODELLI ET AL, ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, (2011-09-15), vol. 31, no. 12, pgs e116 - e127 *
QINGXIAN ZHANG ET AL, "In Vivo Delivery of Gremlin siRNA Plasmid Reveals Therapeutic Potential against Diabetic Nephropathy by Recovering Bone Morphogenetic Protein-7", PLOS ONE, (2010-07-22), vol. 5, no. 7, page e11709 *
S. A. ROXBURGH ET AL, "Allelic Depletion of grem1 Attenuates Diabetic Kidney Disease", DIABETES, (2009-04-28), vol. 58, no. 7, doi:10.2337/db08-1365, ISSN 0012-1797, pages 1641 - 1650 *
S. MITOLA ET AL, "Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2", BLOOD, (2010-11-04), vol. 116, no. 18, doi:10.1182/blood-2010-06-291930, ISSN 0006-4971, pages 3677 - 3680 *

Also Published As

Publication number Publication date
MX369574B (es) 2019-11-13
US20200157194A1 (en) 2020-05-21
US11634480B2 (en) 2023-04-25
MX2015011616A (es) 2015-12-17
JP2019151654A (ja) 2019-09-12
US10377817B2 (en) 2019-08-13
CL2015002603A1 (es) 2016-03-04
CA2904644A1 (en) 2014-10-02
KR20150129718A (ko) 2015-11-20
ZA201506113B (en) 2016-07-27
SG10201707518YA (en) 2017-10-30
US20160024195A1 (en) 2016-01-28
EA201591762A1 (ru) 2015-12-30
HK1220469A1 (zh) 2017-05-05
SG11201506459PA (en) 2015-09-29
BR112015021979A2 (pt) 2017-08-29
EP2970448A1 (en) 2016-01-20
JP2016519650A (ja) 2016-07-07
AU2014241442A1 (en) 2015-10-15
PH12015501865A1 (en) 2015-12-07
CA2904644C (en) 2022-09-20
US20230192831A1 (en) 2023-06-22
ES2898620T3 (es) 2022-03-08
CN105189548A (zh) 2015-12-23
EP2970448B1 (en) 2021-11-03
JP6581075B2 (ja) 2019-09-25
IL240769A0 (en) 2015-10-29
WO2014159010A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
US20230192831A1 (en) Human Antibodies to GREM1
JP7500812B2 (ja) 中東呼吸器症候群－コロナウイルススパイクタンパク質に対するヒト抗体
AU2020200892B2 (en) Anti-activin a antibodies and uses thereof
AU2017245479C1 (en) Anti-PDGFR-beta antibodies and uses thereof
KR102534895B1 (ko) 항-c5 항체 및 이의 용도
AU2016307430B2 (en) Anti-ANGPTL8 antibodies and uses thereof
KR101859911B1 (ko) 사람 ｇｄｆ８에 대한 항체
AU2013280610B2 (en) Anti-EGFR antibodies and uses thereof
AU2013305863B2 (en) Human antibodies to GFRalpha3 and methods of use thereof
DK2475684T3 (en) HUMAN HIGH-EFFICIENCY ANTIBODIES AGAINST HUMAN PROTEASE-ACTIVATED RECEPTOR-2
KR20130132842A (ko) 인간 tnf-유사 리간드 1a(tl1a)에 대한 인간 항체
KR20140009264A (ko) 글루카곤 수용체에 대한 인간 항체
KR20190078650A (ko) 항-angptl8 항체를 사용하는 비만의 치료 방법
CN113993898A (zh) 结合ret的人抗体及其使用方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)